[CAS NO. 1268955-50-5] TXNIP-IN-1
PRODUCTS SPECIFICATIONS [1268955-50-5]
DESCRIPTION [1268955-50-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 248.23 |
| Molecular Formula | C12H12N2O4 |
| SMILES | O=C(O)C(C(C)C)N(C1=O)C(C2=C1C=CN=C2)=O |
1 Publications Citing Use of MCE
Summary
TXNIP-IN-1 is TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex inhibitor extracted from patent US20200085800A1, Compound 1. TXNIP-IN-1 can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease , or inflammatory disease [1] .
IC50 & Target
TXNIP-TRX complex [1]
In Vitro
TXNIP-IN-1 bocks high glucose (HG induced) TXNIP-TRX complex formation
[1]
.
TXNIP-IN-1 (1.25-5 μM) reduces HG-induced expression of TNF in monocytes
[1]
.
TXNIP-IN-1 (1.25-5 μM; 72 hours) inhibits TXNIP mRNA expression in THP1 cells
[1]
.
TXNIP-IN-1 (0.3-10 μM; 72 hours) inhibits TXNIP mRNA expression in murine RAW macrophages
[1]
.
TXNIP-IN-1 (5-20 μM; 72 hours) decreases TXNIP but not TNF-alpha mRNA levels in MIN6 cells
[1]
.
TXNIP-IN-1 (0.62-5 μM; 72 hours) affects TXNIP and TNF-alpha mRNA expression in human pancreas 1.1B4 beta cells
[1]
.
TXNIP-IN-1 (5 μM; 16-72 hours) inhibits c-TRX interaction in THP1 cells cultured in 25mM glucose
[1]
.
TXNIP-IN-1 targets TXNIP mRNA in human pancreatic islets
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 201.43 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.0285 mL | 20.1426 mL | 40.2852 mL |
| 5 mM | 0.8057 mL | 4.0285 mL | 8.0570 mL |
| 10 mM | 0.4029 mL | 2.0143 mL | 4.0285 mL |